Acadia Pharmaceuticals is invested in and embedded within the Rett Syndrome community in a way that most biopharma manufacturers strive for. The company has consistently demonstrated a level of commitment, education, and engagement that enables their team members to show up physically, mentally, and emotionally for the Rett community.

The teams supporting DAYBUE patients and families show what can be achieved when industry expertise and patient passion is combined with an above and beyond commitment to delivering tailored support. These individuals tirelessly champion on behalf of Rett patients and families, taking an integrated, holistic approach to managing the end-to-end DAYBUE journey, including streamlining access processes and collecting insights that drive program improvements.

Rett Syndrome is a complex genetic disorder with a range of symptoms that typically require lifelong care. The unique range of resources and support that Acadia offers helps patients and caregivers feel connected and ultimately, less alone.

Rett Syndrome manifests uniquely in each person, which means that the types of improvements and what they mean for a patient (and their loved ones) can be unique, too. It’s incredibly impactful to hear anecdotes of the meaningful improvements that DAYBUE patients experience in mood, eye gaze, vocalizations, and other Rett behaviors. This can mean everything from hearing a child say “mom” for the first time or laugh in response to a favorite show (“Blue’s Clues”) after being primarily nonverbal to positive family outings for the first time in years.